Physician profile
Anna Rothstein
NPI 1801998109
$764.64
in general payments reported to CMS, 2019-2025
15 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.67 · 2020: $163 · 2021: $21.97 · 2022: $40.98 · 2023: $112 · 2024: $80.41 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152.23 | 2024-2025 | Tepezza |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Bausch & Lomb Americas INC. | $113.98 | 2022-2025 | Miebo, Xiidra |
| Rxsight INC | $54.02 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $52.77 | 2020-2023 | Tepezza |
| Genentech USA, INC. | $39.04 | 2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $36.82 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $29.31 | 2025 | Xdemvy |
| Astellas Pharma US INC | $28.65 | 2023 | |
| Alcon Vision LLC | $23.02 | 2023 | Simbrinza |
| Merz Pharmaceuticals, LLC | $21.97 | 2021 | |
| Dompe US, INC. | $18.32 | 2025 | Oxervate |
| Abbvie INC. | $16.82 | 2025 | |
| Mallinckrodt Enterprises LLC | $14.30 | 2019 | |
| Kaleo, INC. | $13.39 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.